Exploring the relationship between HIV Testing frequency and sexual behavior, prevention prophylaxis use among MSM in Southern China.

PLoS OneSep 29, 2026 (epub)
Clinical ResearchInfectious Diseases

Yinxia Liang, Min Wang, Yun Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the relationship between HIV testing frequency, sexual behaviors, and prophylaxis use among 327 men who have sex with men (MSM) in Guangxi, China. The study found that higher HIV testing frequency was associated with increased use of PrEP and PEP, with a 7.335-fold increase in PrEP use in the high frequency group compared to the low frequency group.

Key findings

  • 76.45% of MSM tested for HIV less frequently than once every three months.
  • Middle-frequency HIV testing was linked to fewer temporary (OR 0.120) and regular sexual partners (OR 0.502).
  • PrEP use increased 7.335-fold in the high frequency group compared to the low frequency group.
  • PEP use showed a 6.129-fold increase in the high frequency group compared to the low frequency group.

Why it matters

Understanding the dynamics between HIV testing frequency and prophylaxis use can inform targeted prevention strategies, potentially reducing HIV transmission rates among high-risk populations such as MSM.

Source

PubMed · PMID 42809564

Published in PLoS One. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.